Anna DeFazio

List of Publications by Citations

190 papers	16,446 citations	49 h-index	127 g-index
224 ext. papers	19,266 ext. citations	7.8 avg, IF	5.16 L-index

#	Paper	IF	Citations
190	Patterns of somatic mutation in human cancer genomes. *Nature*, **2007**, 446, 153-8	50.4	2400
189	Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature*, **2007**, 447, 1087-93	50.4	1957
188	International network of cancer genome projects. *Nature*, **2010**, 464, 993-8	50.4	1613
187	Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. *Clinical Cancer Research*, **2008**, 14, 5198-208	12.9	1044
186	Whole-genome characterization of chemoresistant ovarian cancer. *Nature*, **2015**, 521, 489-94	50.4	890
185	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. *Journal of Clinical Oncology*, **2012**, 30, 2654-63	2.2	810
184	Mutation of FOXL2 in granulosa-cell tumors of the ovary. *New England Journal of Medicine*, **2009**, 360, 2719-29	59.2	551
183	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. *Journal of Pathology*, **2010**, 221, 49-56	9.4	485
182	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. *Journal of Clinical Investigation*, **2013**, 123, 517-25	15.9	371
181	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. *Lancet Oncology, The*, **2013**, 14, 853-62	21.7	248
180	Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. *Clinical Cancer Research*, **2009**, 15, 1417-27	12.9	217
179	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
178	IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. *Clinical Cancer Research*, **2011**, 17, 2538-48	12.9	182
177	Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. *International Journal of Cancer*, **2008**, 122, 170-6	7.5	182
176	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncology*, **2017**, 3, e173290	13.4	152
175	Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. *PLoS ONE*, **2011**, 6, e18064	3.7	143
174	Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. *Molecular Endocrinology*, **1995**, 9, 1804-13		137

173	Immunohistochemical detection of proliferating cells in vivo. *Journal of Histochemistry and Cytochemistry*, **1987**, 35, 571-7	3.4	133
172	Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 4497-501	11.5	126
171	Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. *Clinical Cancer Research*, **2012**, 18, 5806-15	12.9	118
170	Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. *PLoS Genetics*, **2013**, 9, e1003284	6	112
169	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. *Nature Communications*, **2018**, 9, 3970	17.4	111
168	High resolution melting for mutation scanning of TP53 exons 5-8. *BMC Cancer*, **2007**, 7, 168	4.8	108
167	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 652-7	12.9	107
166	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. *Oncotarget*, **2015**, 6, 37663-77	3.3	98
165	Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. *Journal of Pathology* , **2011**, 223, 567-73	9.4	98
164	Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. *Molecular Cancer Research*, **2008**, 6, 1678-90	6.6	93
163	Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 2321-30	4	88
162	ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. *Clinical Cancer Research*, **2008**, 14, 5594-601	12.9	83
161	Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2015**, 113, 817-26	8.7	80
160	ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	79
159	Caring for women with ovarian cancer in the last year of life: a longitudinal study of caregiver quality of life, distress and unmet needs. *Gynecologic Oncology*, **2014**, 132, 690-7	4.9	78
158	LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. *Cancer Research*, **2012**, 72, 4060-73	10.1	73
157	Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. *International Journal of Cancer*, **2005**, 117, 1049-54	7.5	69
156	Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. *Clinical Cancer Research*, **2013**, 19, 3474-84	12.9	67

155	Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 1429-42	5.6	67
154	Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. *Nature Communications*, **2019**, 10, 1295	17.4	66
153	Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. *Clinical Cancer Research*, **2014**, 20, 6618-30	12.9	66
152	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2011**, 20, 4693-706	5.6	66
151	Consortium analysis of 7 candidate SNPs for ovarian cancer. *International Journal of Cancer*, **2008**, 123, 380-388	7.5	66
150	A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. *Cancer Research*, **2017**, 77, 971-981	10.1	64
149	Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. *Medical Journal of Australia*, **2010**, 193, S52-7	4	64
148	Expression of progesterone receptors A and B in the mouse ovary during the estrous cycle. *Endocrinology*, **2004**, 145, 3487-94	4.8	61
147	The molecular origin and taxonomy of mucinous ovarian carcinoma. *Nature Communications*, **2019**, 10, 3935	17.4	59
146	Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 2557-65	4	58
145	Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. *Clinical Cancer Research*, **2011**, 17, 5490-500	12.9	55
144	MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. *Gynecologic Oncology*, **2006**, 100, 239-46	4.9	55
143	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
142	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. *British Journal of Cancer*, **2014**, 111, 2297-307	8.7	49
141	The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. *British Journal of Cancer*, **2008**, 98, 1085-93	8.7	47
140	Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle. *Endocrinology*, **2006**, 147, 5503-12	4.8	47
139	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. *Clinical Cancer Research*, **2018**, 24, 569-580	12.9	46
138	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45

137	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. *Clinical Cancer Research*, **2011**, 17, 3742-50	12.9	45
136	Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". *PLoS Genetics*, **2010**, 6, e1001016	6	42
135	Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2009**, 100, 412-20	8.7	42
134	Body size and risk of epithelial ovarian and related cancers: a population-based case-control study. *International Journal of Cancer*, **2008**, 123, 450-456	7.5	42
133	Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma. *International Journal of Gynecological Pathology*, **2004**, 23, 138-44	3.2	42
132	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nature Communications*, **2015**, 6, 8234	17.4	40
131	MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. *BMC Cancer*, **2010**, 10, 497	4.8	40
130	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. *Gynecologic Oncology*, **2013**, 131, 8-14	4.9	39
129	Prevalence and predictors of insomnia in women with invasive ovarian cancer: anxiety a major factor. *European Journal of Cancer*, **2009**, 45, 3262-70	7.5	39
128	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *Journal of Pathology: Clinical Research*, **2018**, 4, 250-261	5.3	38
127	Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. *Journal of the National Cancer Institute*, **2008**, 100, 437-42	9.7	38
126	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. *BMC Medicine*, **2015**, 13, 156	11.4	37
125	Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group. *Journal of Clinical Oncology*, **2011**, 29, 2253-8	2.2	37
124	Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). *Gynecologic Oncology*, **2014**, 133, 16-22	4.9	36
123	Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line--a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. *Cancer Chemotherapy and Pharmacology*, **2001**, 48, 229-34	3.5	35
122	Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: a prospective population-based study over the last year of life. *Gynecologic Oncology*, **2013**, 130, 162-8	4.9	33
121	Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. *American Journal of Clinical Nutrition*, **2015**, 102, 109-14	7	33
120	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32

119	and Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. *Cancer Research*, **2017**, 77, 4268-4278	10.1	32
118	Focal subnuclear distribution of progesterone receptor is ligand dependent and associated with transcriptional activity. *Molecular Endocrinology*, **2007**, 21, 14-29		32
117	Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. *Journal of Circulating Biomarkers*, **2018**, 7, 1849454418782617	3.3	31
116	Expression and tyrosine phosphorylation of EMS1 in human breast cancer cell lines. *International Journal of Cancer*, **1996**, 68, 485-92	7.5	29
115	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2016**, 115, 95-101	8.7	28
114	Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. *PLoS ONE*, **2011**, 6, e17617	3.7	28
113	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Research*, **2019**, 79, 505-517	10.1	28
112	Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. *British Journal of Cancer*, **2016**, 114, 417-26	8.7	27
111	Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. *Journal of the National Cancer Institute*, **2008**, 100, 1519-29	9.7	26
110	Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer. *Clinical Cancer Research*, **2008**, 14, 6924-32	12.9	26
109	Strategies to enable large-scale proteomics for reproducible research. *Nature Communications*, **2020**, 11, 3793	17.4	26
108	Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study. *Gynecologic Oncology*, **2013**, 129, 310-7	4.9	25
107	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. *Clinical Cancer Research*, **2015**, 21, 5264-76	12.9	24
106	Scientists and clinicians test their metal-back to the future with platinum compounds. *Lancet Oncology, The*, **2002**, 3, 312-8	21.7	24
105	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. *Gynecologic Oncology*, **2019**, 154, 531-538	4.9	23
104	Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. *Oncogene*, **2015**, 34, 485-95	9.2	23
103	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Modern Pathology*, **2019**, 32, 1834-1846	9.8	21
102	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clinical Cancer Research*, **2020**, 26, 5411-5423	12.9	21

101	Therapeutic options for mucinous ovarian carcinoma. *Gynecologic Oncology*, **2020**, 156, 552-560	4.9	21
100	The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. *Human Molecular Genetics*, **2016**, 25, 5460-5471	5.6	20
99	Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival. *Gynecologic Oncology*, **2014**, 132, 566-72	4.9	20
98	Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. *Scientific Reports*, **2014**, 4, 4669	4.9	20
97	Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunology Research*, **2014**, 2, 332-40	12.5	20
96	Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 987-92	4	20
95	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. *Cancer Causes and Control*, **2017**, 28, 469-486	2.8	19
94	Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. *Oncotarget*, **2016**, 7, 6353-68	3.3	19
93	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. *International Journal of Cancer*, **2017**, 140, 2422-2435	7.5	18
92	Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. *Cancer Epidemiology*, **2015**, 39, 196-9	2.8	18
91	Copy number aberrations in benign serous ovarian tumors: a case for reclassification?. *Clinical Cancer Research*, **2011**, 17, 7273-82	12.9	18
90	RAD51B in Familial Breast Cancer. *PLoS ONE*, **2016**, 11, e0153788	3.7	18
89	FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. *British Journal of Cancer*, **2020**, 122, 361-371	8.7	18
88	Going to extremes: determinants of extraordinary response and survival in patients with cancer. *Nature Reviews Cancer*, **2019**, 19, 339-348	31.3	17
87	Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. *Supportive Care in Cancer*, **2018**, 26, 4133-4142	3.9	17
86	Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. *Gynecologic Oncology*, **2018**, 150, 239-246	4.9	17
85	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. *British Journal of Cancer*, **2020**, 123, 793-802	8.7	16
84	DNA of mouse mammary tumor virus-like virus is present in human tumors influenced by hormones. *Journal of Medical Virology*, **2010**, 82, 1044-50	19.7	16

83	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
82	Inverse regulation of oestrogen receptor and epidermal growth factor receptor gene expression in MCF-7 breast cancer cells treated with phorbol ester. *Journal of Steroid Biochemistry and Molecular Biology*, **1996**, 58, 267-75	5.1	15
81	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. *Journal of Pathology*, **2021**, 253, 41-54	9.4	15
80	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clinic Proceedings*, **2018**, 93, 307-320	6.4	14
79	Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years. *International Journal of Gynecological Cancer*, **2010**, 20, 757-65	3.5	14
78	Rapid fluorometric detection of drug resistant tumour cells. *British Journal of Cancer*, **1985**, 52, 633-6	8.7	14
77	High levels of genomic aberrations in serous ovarian cancers are associated with better survival. *PLoS ONE*, **2013**, 8, e54356	3.7	14
76	New Approaches to Continuing Medical Education: a QStream (spaced education) Program for Research Translation in Ovarian Cancer. *Journal of Cancer Education*, **2017**, 32, 476-482	1.8	13
75	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, **2017**, 28, 459-468	2.8	13
74	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. *Gynecologic Oncology*, **2016**, 142, 458-64	4.9	13
73	Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. *International Journal of Gynecological Cancer*, **2017**, 27, 900-906	3.5	12
72	Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer. *Translational Oncology*, **2017**, 10, 346-356	4.9	12
71	Modulation of antifolate cytotoxicity by metabolites from dying cells in a lymphocyte clonal assay. *British Journal of Cancer*, **1988**, 57, 459-63	8.7	12
70	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *American Journal of Human Genetics*, **2020**, 107, 837-848	11	12
69	Population-based targeted sequencing of 54 candidate genes identifies as a susceptibility gene for high-grade serous ovarian cancer. *Journal of Medical Genetics*, **2021**, 58, 305-313	5.8	12
68	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2017**, 116, 1223-1228	8.7	11
67	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. *British Journal of Cancer*, **2017**, 117, 1063-1069	8.7	11
66	Variation in NF-B signaling pathways and survival in invasive epithelial ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1421-7	4	11

65	Global gene expression profiles of ovarian surface epithelial cells in vivo. *Journal of Molecular Endocrinology*, **2008**, 40, 281-96	4.5	11
64	Coordinate regulation of oestrogen and prolactin receptor expression by sodium butyrate in human breast cancer cells. *Biochemical and Biophysical Research Communications*, **1992**, 182, 740-5	3.4	11
63	Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?. *Supportive Care in Cancer*, **2016**, 24, 2627-34	3.9	11
62	Acquired Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. *Cancer Research*, **2021**, 81, 4709-4722	10.1	11
61	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. *Journal of Gynecologic Oncology*, **2019**, 30, e86	4	10
60	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, **2019**, 30, 537-547	2.8	9
59	The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function. *Cellular Signalling*, **2015**, 27, 1763-71	4.9	9
58	Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. *Gynecologic Oncology*, **2018**, 150, 527-533	4.9	9
57	Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.. *JCO Precision Oncology*, **2018**, 2, 1-14	3.6	9
56	Accelerated Barocycler Lysis and Extraction Sample Preparation for Clinical Proteomics by Mass Spectrometry. *Journal of Proteome Research*, **2019**, 18, 399-405	5.6	9
55	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2018**, 47, 450-459	7.8	8
54	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 780-90	4	8
53	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1470-1473	4	8
52	Genome-wide association study for ovarian cancer susceptibility using pooled DNA. *Twin Research and Human Genetics*, **2012**, 15, 615-623	2.2	8
51	Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study. *International Journal of Cancer*, **2021**, 148, 1608-1615	7.5	8
50	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 217-228	4	7
49	High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq. *PLoS ONE*, **2015**, 10, e0143006	3.7	7
48	Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer. *JNCI Cancer Spectrum*, **2018**, 2, pky047	4.6	7

47	When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. *Gynecologic Oncology*, **2020**, 159, 179-186	4.9	6
46	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 446-54	4	6
45	Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis. *Gynecologic Oncology*, **2014**, 132, 130-6	4.9	6
44	Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. *Gynecologic Oncology*, **2005**, 97, 16-25	4.9	6
43	Evidence against the compartmentation of adenosine kinase and adenosine deaminase activities in human erythrocytes. *FEBS Letters*, **1980**, 113, 215-7	3.8	6
42	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. *Modern Pathology*, **2021**, 34, 194-206	9.8	6
41	A healthy lifestyle and survival among women with ovarian cancer. *International Journal of Cancer*, **2020**, 147, 3361-3369	7.5	5
40	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. *Gynecologic Oncology*, **2020**, 158, 702-709	4.9	5
39	ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. *International Journal of Cancer*, **2020**, 147, 2225-2238	7.5	5
38	Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium. *Twin Research and Human Genetics*, **2009**, 12, 269-75	2.2	5
37	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. *Oncotarget*, **2017**, 8, 64670-64684	3.3	5
36	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine*, **2019**, 8, 2503-2513	4.8	4
35	Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines. *Mutation Research DNA Repair*, **1998**, 407, 243-52		4
34	The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.. *Journal of Clinical Oncology*, **2018**, 36, 10081-10081	2.2	4
33	Insomnia and its association with quality of life in women with ovarian cancer. *Gynecologic Oncology* , **2020**, 158, 760-768	4.9	4
32	Increased prevalence of obstructive sleep apnea in women diagnosed with endometrial or breast cancer. *PLoS ONE*, **2021**, 16, e0249099	3.7	4
31	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
30	Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. *Scientific Reports*, **2018**, 8, 1508	4.9	3

29	Enumeration of 6-thioguanine-resistant tumour cells using flow cytometry and comparison with a microtitration cloning assay. *Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology*, **1989**, 216, 57-64		3
28	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. *Journal of Pathology*, **2021**,	9.4	3
27	Pre- and Post-Diagnosis Diet Quality and Ovarian Cancer Survival. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 229-232	4	3
26	Survival in patients with BRCA mutation-positive platinum-sensitive recurrent ovarian cancer.. *Journal of Clinical Oncology*, **2014**, 32, e16519-e16519	2.2	2
25	Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).. *Journal of Clinical Oncology*, **2018**, 36, 10062-10062	2.2	2
24	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**,	5.1	2
23	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2021**,	4	2
22	The Ovarian cancer Prognosis And Lifestyle (OPAL) study.. *Journal of Clinical Oncology*, **2018**, 36, 88-88	2.2	2
21	Abstract A25: BRAFV600E mutations in serous ovarian cancer and response to the BRAF inhibitor, dabrafenib. **2016**,		2
20	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. *Human Genetics and Genomics Advances*, **2021**, 2, 100042-100042	0.8	2
19	Identification of a Locus Near Associated With Progression-Free Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 1669-1680	4	2
18	Irregular Sleep/Wake Patterns Are Associated With Reduced Quality of Life in Post-treatment Cancer Patients: A Study Across Three Cancer Cohorts. *Frontiers in Neuroscience*, **2021**, 15, 700923	5.1	2
17	Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines **2000**, 87, 487		2
16	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 680-688	4	1
15	Characterization of ovarian cancer long-term responders on olaparib.. *Journal of Clinical Oncology*, **2014**, 32, 5534-5534	2.2	1
14	New therapeutic opportunities for women with low-grade serous ovarian cancer. *Endocrine-Related Cancer*, **2021**, 29, R1-R16	5.7	1
13	Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma		1
12	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1

11	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.. *Journal of Clinical Oncology*, **2016**, 34, 5553-5553	2.2	1
10	Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. *Gynecologic Oncology*, **2021**, 162, 720-727	4.9	1
9	Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma		1
8	Regional variation in extracellular purine levels in vivo. *Advances in Experimental Medicine and Biology*, **1984**, 165 Pt A, 301-4	3.6	1
7	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *British Journal of Cancer*, **2021**, 125, 1135-1145	8.7	0
6	Cancer sleep symptom-related phenotypic clustering differs across three cancer specific patient cohorts.. *Journal of Sleep Research*, **2022**, e13588	5.8	0
5	Tumour profiling for treatment of patients with ovarian cancers. *Pathology*, **2018**, 50, S77	1.6	
4	The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.. *Journal of Clinical Oncology*, **2018**, 36, 155-155	2.2	
3	When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.. *Journal of Clinical Oncology*, **2018**, 36, 172-172	2.2	
2	Genome-wide association study for identification of candidate SNPs associated with carboplatin and paclitaxel clearance in ovarian cancer patients.. *Journal of Clinical Oncology*, **2014**, 32, 5563-5563	2.2	
1	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment **2021**, 1-23		